Latest news and press releases about Artelo Biosciences, Inc. (ARTL): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory...
Price
| Price | $3.75 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.23 |
| EV / EBITDA | 0.15 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -519.09% |
| Return on Invested Capital | -219.36% |
| Return on Assets | -196.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CARM · GTBP · LIPO · PBM · PTIX · REVB · SLRX
Explore sector: Healthcare · Biotechnology
More sections of ARTL: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks